ZA815793B - Suspension of microencapsulated bacampicillin acid addition salt for oral,especially pediatric administration - Google Patents

Suspension of microencapsulated bacampicillin acid addition salt for oral,especially pediatric administration

Info

Publication number
ZA815793B
ZA815793B ZA815793A ZA815793A ZA815793B ZA 815793 B ZA815793 B ZA 815793B ZA 815793 A ZA815793 A ZA 815793A ZA 815793 A ZA815793 A ZA 815793A ZA 815793 B ZA815793 B ZA 815793B
Authority
ZA
South Africa
Prior art keywords
microencapsulated
oral
suspension
acid addition
addition salt
Prior art date
Application number
ZA815793A
Other languages
English (en)
Inventor
Morgan Lee Beatty
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA815793B publication Critical patent/ZA815793B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
ZA815793A 1980-08-22 1981-08-21 Suspension of microencapsulated bacampicillin acid addition salt for oral,especially pediatric administration ZA815793B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/180,537 US4321253A (en) 1980-08-22 1980-08-22 Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration

Publications (1)

Publication Number Publication Date
ZA815793B true ZA815793B (en) 1982-08-25

Family

ID=22660812

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA815793A ZA815793B (en) 1980-08-22 1981-08-21 Suspension of microencapsulated bacampicillin acid addition salt for oral,especially pediatric administration

Country Status (41)

Country Link
US (1) US4321253A (fr)
JP (1) JPS5775986A (fr)
KR (1) KR860000513B1 (fr)
AR (1) AR227201A1 (fr)
AT (1) AT370994B (fr)
AU (1) AU529965B2 (fr)
BE (1) BE890028A (fr)
BG (1) BG42000A3 (fr)
CA (1) CA1137414A (fr)
CH (1) CH650674A5 (fr)
CS (1) CS225845B2 (fr)
DD (1) DD201644A5 (fr)
DE (1) DE3132614C2 (fr)
DK (1) DK158971C (fr)
DZ (1) DZ315A1 (fr)
ES (1) ES8303091A1 (fr)
FI (1) FI72647C (fr)
FR (1) FR2488798A1 (fr)
GB (1) GB2082539B (fr)
GR (1) GR74983B (fr)
HK (1) HK43786A (fr)
HU (1) HU188679B (fr)
IE (1) IE51506B1 (fr)
IL (1) IL63617A (fr)
IN (1) IN156538B (fr)
IT (1) IT1138161B (fr)
KE (1) KE3626A (fr)
LU (1) LU83572A1 (fr)
MX (1) MX5731A (fr)
MY (1) MY8600597A (fr)
NL (1) NL191978C (fr)
NO (1) NO154821C (fr)
NZ (1) NZ198106A (fr)
PH (1) PH17125A (fr)
PL (1) PL232141A1 (fr)
PT (1) PT73555B (fr)
RO (1) RO82679B (fr)
SE (1) SE448819B (fr)
SU (1) SU1364226A3 (fr)
YU (1) YU43985B (fr)
ZA (1) ZA815793B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH647676A5 (fr) * 1978-12-22 1985-02-15 Donald E Panoz Formes galeniques a usage oral, a liberation programmee et leurs procedes de preparation.
SE8103843L (sv) * 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
SE8203953D0 (sv) * 1982-06-24 1982-06-24 Astra Laekemedel Ab Pharmaceutical mixture
US4994260A (en) * 1982-05-28 1991-02-19 Astra Lakemedel Aktiebolag Pharmaceutical mixture
WO1984000004A1 (fr) * 1982-06-14 1984-01-05 Key Pharma Aspirine a liberation entretenue
US4508702A (en) * 1982-06-14 1985-04-02 Key Pharmaceuticals, Inc. Sustained release aspirin
WO1984000295A1 (fr) * 1982-07-09 1984-02-02 Key Pharma Forme de dosage de quinidine a liberation entretenue
US4634587A (en) * 1982-07-09 1987-01-06 Key Pharmaceuticals, Inc. Sustained release quinidine dosage form
AU569277B2 (en) * 1983-03-03 1988-01-28 Dow Chemical Company, The Aqueuos dispersion of water-insoluble organophilic cellulose ether for sustained release of active agents
US4555399A (en) * 1983-11-18 1985-11-26 Key Pharmaceuticals, Inc. Aspirin tablet
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
SE8405611D0 (sv) * 1984-11-09 1984-11-09 Astra Laekemedel Ab Process for stabilization of bacampicillin hydrochloride
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
US4853229A (en) * 1987-10-26 1989-08-01 Alza Corporation Method for adminstering tiny pills
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
NZ252433A (en) * 1992-04-30 1996-07-26 Schering Corp Preparation of a dry hydrated cephalosporin powder formulation which is resistant to air oxidation and dehydration by mixing the drug with dry excipients and filling into a sealable storage container
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
US6270804B1 (en) * 1998-04-03 2001-08-07 Biovail Technologies Ltd. Sachet formulations
IN191482B (fr) * 1999-03-19 2003-12-06 Ranbaxy Lab Ltd
JP4711478B2 (ja) * 1999-08-13 2011-06-29 旭化成ケミカルズ株式会社 味がマスクされた薬物
US20050037086A1 (en) * 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
MXPA02006324A (es) 1999-12-23 2002-12-13 Pfizer Prod Inc Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco.
EP1118333A1 (fr) * 2000-01-18 2001-07-25 Eurand International S.P.A. Compositions avec une biodisponibilité orale augmentée
US6551617B1 (en) 2000-04-20 2003-04-22 Bristol-Myers Squibb Company Taste masking coating composition
ATE361061T1 (de) 2000-04-20 2007-05-15 Novartis Ag Beschichtungszusammensetzung zur geschmacksmaskierung
US20040142475A1 (en) * 2000-06-02 2004-07-22 Barman Shikha P. Delivery systems for bioactive agents
FR2822834B1 (fr) * 2001-04-02 2005-02-25 Flamel Tech Sa Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation
EP1390015A1 (fr) * 2001-05-31 2004-02-25 Cima Labs Inc. Masquage du gout de medicaments hautement hydrosolubles
KR20030015655A (ko) * 2001-08-17 2003-02-25 한미약품공업 주식회사 항암제의 경구흡수율을 증가시키는 인단계 화합물의결정성 산부가염, 이의 제조방법 및 이를 함유하는 약학적조성물
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
JP4698950B2 (ja) * 2002-04-09 2011-06-08 フラメル・テクノロジー アモキシシリンの改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
PT1492511E (pt) 2002-04-09 2009-04-09 Flamel Tech Sa Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
FR2842736B1 (fr) 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
FR2842735B1 (fr) * 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
FR2843117B1 (fr) * 2002-07-30 2004-10-15 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques
US7632521B2 (en) * 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
FR2860516B1 (fr) * 2003-10-03 2006-01-13 Flamel Tech Sa Homopolyaminoacides telecheliques fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
FR2862536B1 (fr) * 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
FR2885526B1 (fr) * 2005-05-13 2007-07-27 Flamel Technologies Sa Medicament oral a base d'inhibiteur de pompe a protons
CN108601796B (zh) * 2015-10-13 2020-03-03 技术防卫株式会社 胃肠道粘膜保护组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3549746A (en) * 1967-11-02 1970-12-22 Bristol Myers Co Antibiotic composition
US3873521A (en) * 1970-09-17 1975-03-25 Astra Laekemedel Ab Esters of {60 -amino penicillins
ZA718014B (en) 1970-12-23 1972-08-30 Beecham Group Ltd Pharmaceutical formulations
US4016254A (en) * 1972-05-19 1977-04-05 Beecham Group Limited Pharmaceutical formulations
GB1455296A (en) * 1973-05-24 1976-11-10 Beecham Group Ltd Veterinary treatment
GB1479655A (en) 1974-03-08 1977-07-13 Beecham Group Ltd Antibiotic preparations
US4127647A (en) * 1975-04-08 1978-11-28 Meiji Seika Kaisha, Ltd. Process for preparation of stable amorphous macrolide antibiotic solids
JPS5840529B2 (ja) * 1975-09-29 1983-09-06 明治製菓株式会社 ケイコウヨウセイザイノセイホウ
GB1561301A (en) * 1976-01-02 1980-02-20 Beecham Group Ltd Orally administrable pharmaceutical composition
ZA793935B (en) * 1978-08-04 1980-07-30 Beecham Group Ltd Powders
JPS57105316A (en) * 1980-12-23 1982-06-30 Hitachi Cable Ltd Method of fitting heat-shrinkable tube

Also Published As

Publication number Publication date
FI812574L (fi) 1982-02-23
SE8104974L (sv) 1982-02-23
NL191978B (nl) 1996-08-01
GB2082539B (en) 1984-01-18
AR227201A1 (es) 1982-09-30
KR830005850A (ko) 1983-09-14
RO82679B (ro) 1984-07-30
JPH0248525B2 (fr) 1990-10-25
NO154821C (no) 1987-01-07
MX5731A (es) 1993-11-01
SE448819B (sv) 1987-03-23
IT1138161B (it) 1986-09-17
ES504905A0 (es) 1983-02-01
NL191978C (nl) 1996-12-03
IE811911L (en) 1982-02-22
DE3132614A1 (de) 1982-05-19
ES8303091A1 (es) 1983-02-01
YU201781A (en) 1984-04-30
IN156538B (fr) 1985-08-31
KR860000513B1 (ko) 1986-05-02
MY8600597A (en) 1986-12-31
BG42000A3 (en) 1987-09-15
SU1364226A3 (ru) 1987-12-30
FI72647B (fi) 1987-03-31
HU188679B (en) 1986-05-28
CH650674A5 (fr) 1985-08-15
IE51506B1 (en) 1987-01-07
KE3626A (en) 1986-05-16
BE890028A (fr) 1982-02-22
GB2082539A (en) 1982-03-10
IL63617A0 (en) 1981-11-30
CS225845B2 (en) 1984-02-13
NO154821B (no) 1986-09-22
DD201644A5 (de) 1983-08-03
PT73555A (en) 1981-09-01
PL232141A1 (fr) 1982-03-15
DE3132614C2 (de) 1985-08-22
AU7441681A (en) 1982-04-01
FI72647C (fi) 1987-07-10
YU43985B (en) 1990-02-28
US4321253A (en) 1982-03-23
AT370994B (de) 1983-05-25
RO82679A (fr) 1984-05-23
FR2488798B1 (fr) 1985-01-11
NZ198106A (en) 1983-12-16
CA1137414A (fr) 1982-12-14
DK158971C (da) 1991-01-07
DZ315A1 (fr) 2004-09-13
PH17125A (en) 1984-06-01
FR2488798A1 (fr) 1982-02-26
AU529965B2 (en) 1983-06-30
IT8123587A0 (it) 1981-08-20
HK43786A (en) 1986-06-20
IL63617A (en) 1984-11-30
ATA362781A (de) 1982-10-15
NO812827L (no) 1982-02-23
DK158971B (da) 1990-08-13
JPS5775986A (en) 1982-05-12
LU83572A1 (fr) 1982-04-14
GR74983B (fr) 1984-07-12
NL8103902A (nl) 1982-03-16
DK372181A (da) 1982-02-23
PT73555B (en) 1983-07-14

Similar Documents

Publication Publication Date Title
KE3626A (en) Suspension of microencapsulated bacampicillin acid addition salt for oral,especially pediatric,administration
IL73594A (en) Carriers for the preparation of controlled long-acting pharmaceuticals for oral administration
AU2823284A (en) Apparatus for the oral administration of capsules to animals
IL73125A0 (en) 1-benzyl-aminoalkyl-pyrrolidinones and acid addition salts thereof,their preparation and pharmaceutical compositions containing them
JPS5742651A (en) Non-hygroscopic salt of 4-hydroxybutyric acid, manufacture and drug containing same
GB2130580B (en) Derivatives of 4-oxo-1, 4-dihydronicotinic acid
EP0319767A3 (en) Process for the preparation of trifluoromethane sulfonique acid chloride
JPS5726641A (en) Use of substituted derivative of 4-phenyl-4-oxo-2-butenoic acid as drug
IL64732A0 (en) Carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
PT82903A (en) Process for the preparation of quinolonecarboxylic acid derivative
EP0203506B1 (en) Process for the preparation of 4,4'-dinitrostilbene-disulfonic acid
PT79616A (en) Process for the preparation of quinolonecarboxylic acid derivatives
JPS56167636A (en) Use of 4-phenyl-4-oxy-2-hydroxybutanoic acid substitution derivative as drug
IL65355A0 (en) Prostanoic acid derivatives
PH24982A (en) Aqueous formulations containing piperidinylcyclopentylheptenoic acid derivatives
GB2207138B (en) Preparation of nucleic acid derivatives.
NO164599C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktivt 7-d-mandelamido-3-(1-sulfometyl-tetrazol-5-yl)-tiometyl-3-cefem-4-karboksylsyre-mononatriumsalt.
GR862445B (en) Process for the preparation of ranitidine or acid addition salts thereof
JPS57183737A (en) Use of phenylaliphatic carboxylic acid derivative as drug
IL64806A0 (en) Cephalosporanic acid derivatives,their preparation and pharmaceutical compositions containing them
IL86930A0 (en) Preparation of piperidinylcyclopentylheptenoic acid derivatives
ZA845743B (en) Halogenoalkylcarbamic acid esters,processes for their preparation and their use as agents for combating pests
EP0320727A3 (en) Process for the preparation of cysteamine acid addition salts
GB2111054B (en) Preparation of formyl-butyric acid derivatives
IE870795L (en) Substituted 4-amino-3-hydtoxybutyric acid derivatives,¹processes for their preparation, agents containing these¹compounds and their use